back to US directory
us clinical guidance

Empagliflozin (Jardiance) for chronic kidney disease

FDA-label and KDIGO positioning, kidney and volume assessment, ketoacidosis and infection safety, and coordinated CKD follow-up.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with CKD at risk of progression being considered for empagliflozin under current US labeling, whether or not type 2 diabetes is present when the indication permits. This page does not cover type 1 diabetes, ketoacidosis treatment, dialysis or full diabetes and heart-failure algorithms.
sources for this section:FDA Jardiance labelKDIGO CKD 2024

The Bottom Line

  • The current US Jardiance label includes adults with CKD at risk of progression to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization.
  • Confirm the labeled population and its limitations, including kidney diseases or treatments for which effectiveness is not expected, before extrapolating from general CKD evidence.
  • Check renal function, volume status and blood pressure before initiation and follow the current label for use at low eGFR; glycemic efficacy and cardiorenal indication are not the same question.
  • Expect and interpret an early hemodynamic eGFR change in context, but investigate progressive decline, hypotension, severe volume loss or another acute kidney insult.
  • Use empagliflozin alongside, not instead of, indicated blood-pressure, renin-angiotensin-system, lipid, diabetes and albuminuria treatment and individualized lifestyle support.
sources for this section:FDA Jardiance labelKDIGO CKD 2024

Practical clinical workflow

1
Document the CKD indication and progression risk, eGFR, albuminuria when available, volume, blood pressure, glucose, recent ketosis and infection, and current diuretic and insulin therapy.
2
Prescribe the label-supported dose, counsel on genital and urinary infection symptoms, hydration, acute-illness interruption and ketoacidosis warning signs, and schedule reassessment.
3
Recheck physiology and renal function at an interval matched to frailty, diuretics and baseline kidney function; change co-medication only when the patient’s response requires it.
4
Hold for the current label interval before major surgery or prolonged fasting and restart after risk factors resolve, oral intake resumes and the patient is clinically stable.
5
If nausea, abdominal pain, vomiting, dyspnea or unexplained acidosis occurs, test for ketoacidosis regardless of glucose level and treat under an emergency protocol.
sources for this section:FDA Jardiance labelKDIGO CKD 2024

Safety boundaries and escalation

  • Jardiance is not recommended for glycemic control in type 1 diabetes and can precipitate ketoacidosis; never compensate for SGLT2 initiation with unsafe insulin withdrawal.
  • Volume depletion, hypotension and acute kidney injury risk requires particular attention in older adults, people with impaired renal function and those taking loop diuretics.
  • Promptly evaluate serious urinary infection, recurrent genital infection or pain, swelling and systemic illness suggesting perineal necrotizing fasciitis.
  • Use current FDA advice for pregnancy, lactation, dialysis, perioperative care and severe acute illness; a stable outpatient plan is not an instruction to continue through every crisis.
sources for this section:FDA Jardiance label

Localization

Formularies may prefer one SGLT2 inhibitor, but products are not automatically interchangeable for every labeled indication or renal threshold.
sources for this section:FDA Jardiance labelKDIGO CKD 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. U.S. Food and Drug AdministrationJARDIANCE (empagliflozin) tablets, current US prescribing informationDrugs@FDA application 204629; current label checked 2026-08-20 · accessed 2026-08-20
    view source
  2. Kidney Disease: Improving Global OutcomesKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseDOI 10.1016/j.kint.2023.10.018 · published 2024-03-13 · accessed 2026-08-20
    view source
  3. American Diabetes Association Professional Practice Committee for DiabetesStandards of Care in Diabetes—20262026 Standards of Care, including living online updates · published 2025-12-08 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.